Proactive Investors - Run By Investors For Investors

ImmunoPrecise boosts screening capability with lab equipment purchase

A second Intellicyt iQue Screener PLUS device allows scientists to reduce lead discovery time while conserving samples and reducing reagent cost
An illustration of antibodies
The equipment upgrade advances ImmunoPrecise's strategic vision, according to the company

ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) (CVE:IPA) said Tuesday that it has acquired additional integrated laboratory equipment for high-throughput antibody screening.

The Victoria, British Columbia, biotech company said in a statement that its purchase of a second Intellicyt iQue Screener PLUS allows its scientists to reduce lead discovery time while conserving samples and reducing reagent cost.

READ: Immunoprecise Antibodies reports 2Q revenue doubled on increased capacity, European expansion

Other antibody screeners, according to the company, report on binding one target at a time, which makes the discovery process time-consuming and can require large amounts of target protein.

"The decision to acquire a second Intellicyt iQue will further support IPA's strategic vision of continued growth and expansion in providing end-to-end therapeutic antibody discovery services to a rapidly expanding list of pharma and biotech clients," said CEO Jennifer Bath in a statement.

The company operates globally to offer antibody services from target analysis to pre-clinical studies. It works out of labs in Victoria as well as in Utrecht and Oss in the Netherlands.

Shares traded at C$0.68 in Monday’s Canadian trading. They were down US$0.04 to US$0.51 on the OTC Markets.

Contact Dennis Fitzgerald at [email protected]

View full IPA profile View Profile

Immunoprecise Antibodies Ltd Timeline

Related Articles

Cancer cells
Tue
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
1534940807_rsz_shutterstock_130327115.jpg
August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use